King/Mylan Merger Will Provide Critical Mass To Develop Palatin ED Agent
Mylan's acquisition of King will provide the critical mass necessary to develop PT-141, a Phase II intranasal sexual dysfunction agent in-licensed from Palatin, King said
Mylan's acquisition of King will provide the critical mass necessary to develop PT-141, a Phase II intranasal sexual dysfunction agent in-licensed from Palatin, King said